This extension study was to monitor the long-term safety and efficacy of rhGAA treatment in a single patient with infantile-onset Pompe disease who were previously treated with rhGAA in a Genzyme study.

Inclusion Criteria:

• Provide written informed consent prior to participating in any study related procedures;
• Currently enrolled in Protocol AGLU01402
• Have the ability to comply with the clinical protocol, which required extensive clinical evaluations for an extended period of time.

Exclusion Criteria:

• Was pregnant or unwilling to use approved birth control during the course of the study;
• Had experienced any unmanageable AEs under Protocol AGLU01402 (as determined and agreed upon by the Principal Investigator and sponsor) due to rhGAA that would preclude continuing ERT;
• Was participating in any other investigational study.